{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T09:40:35Z","timestamp":1793871635688,"version":"4.6.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2022,8,11]],"date-time":"2022-08-11T00:00:00Z","timestamp":1660176000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,8,11]],"date-time":"2022-08-11T00:00:00Z","timestamp":1660176000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100011725","name":"Servier","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1007\/s12325-022-02218-x","type":"journal-article","created":{"date-parts":[[2022,8,11]],"date-time":"2022-08-11T12:02:38Z","timestamp":1660219358000},"page":"4413-4422","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["New Perspectives on Micronised Purified Flavonoid Fraction in Chronic Venous Disease: From Microvalves to Clinical Effectiveness"],"prefix":"10.1007","volume":"39","author":[{"given":"Eliete","family":"Bouskela","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marzia","family":"Lugli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3912-7394","authenticated-orcid":false,"given":"Andrew","family":"Nicolaides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,11]]},"reference":[{"issue":"Suppl 1","key":"2218_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12325-019-0882-6","volume":"36","author":"AN Nicolaides","year":"2019","unstructured":"Nicolaides AN, Labropoulos N. Burden and suffering in chronic venous disease. Adv Ther. 2019;36(Suppl 1):1\u20134.","journal-title":"Adv Ther"},{"issue":"1","key":"2218_CR2","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1053\/j.semvascsurg.2021.02.007","volume":"34","author":"Y Kim","year":"2021","unstructured":"Kim Y, Png CYM, Sumpio BJ, DeCarlo CS, Dua A. Defining the human and health care costs of chronic venous insufficiency. Semin Vasc Surg. 2021;34(1):59\u201364.","journal-title":"Semin Vasc Surg"},{"issue":"1 Suppl","key":"2218_CR3","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1177\/0268355516628359","volume":"31","author":"S Onida","year":"2016","unstructured":"Onida S, Davies AH. Predicted burden of venous disease. Phlebology. 2016;31(1 Suppl):74\u20139.","journal-title":"Phlebology"},{"issue":"3","key":"2218_CR4","doi-asserted-by":"publisher","first-page":"181","DOI":"10.23736\/S0392-9590.18.03999-8","volume":"37","author":"A Nicolaides","year":"2018","unstructured":"Nicolaides A, Kakkos S, Baekgaard N, et al. Management of chronic venous disorders of the lower limbs. Guidelines according to scientific evidence. Part I. Int Angiol. 2018;37(3):181\u2013254.","journal-title":"Int Angiol"},{"issue":"Suppl 1","key":"2218_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12325-019-01218-8","volume":"37","author":"AN Nicolaides","year":"2020","unstructured":"Nicolaides AN. The benefits of micronized purified flavonoid fraction (MPFF) throughout the progression of chronic venous disease. Adv Ther. 2020;37(Suppl 1):1\u20135.","journal-title":"Adv Ther"},{"key":"2218_CR6","doi-asserted-by":"crossref","unstructured":"de Almeida CF, Blanc-Guilemaud V, Bouskela E. Time course of microvalve pathophysiology in high pressure low flow model of venous insufficiency and the role of micronized purified flavonoid fraction. Int Angiol. 2021;40(5):388\u201394.","DOI":"10.23736\/S0392-9590.21.04726-X"},{"issue":"2","key":"2218_CR7","doi-asserted-by":"publisher","first-page":"169","DOI":"10.23736\/S0392-9590.18.03901-9","volume":"37","author":"M Lugli","year":"2018","unstructured":"Lugli M, Maleti O, Iabichella ML, Perrin M. Investigation of non-saphenous veins in C0S patients. Int Angiol. 2018;37(2):169\u201375.","journal-title":"Int Angiol"},{"issue":"5","key":"2218_CR8","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/j.ejvs.2018.02.009","volume":"55","author":"CDSM Gracas","year":"2018","unstructured":"Gracas CDSM, Cyrino FZ, de Carvalho JJ, Blanc-Guillemaud V, Bouskela E. Protective effects of micronized purified flavonoid fraction (MPFF) on a novel experimental model of chronic venous hypertension. Eur J Vasc Endovasc Surg. 2018;55(5):694\u2013702.","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"2218_CR9","unstructured":"Bouskela E, de Almeida Cyrino G, Zely F, Blanc-Guillemaud V, Lucien A. Evaluation of microvalve alterations and assessment of MPFF treatment in an experimental model of venous hypertension 21st Annual Meeting of the European Venous Forum; 24\u201326 June 2021; Virtual2021."},{"key":"2218_CR10","unstructured":"Lugli M, Longhi M, Guerzoni S, Maleti O. Effect of micronized purified flavonoid fraction treatment on microscopic venous valves reflux in C0s and C1s patients with chronic venous disease. 21st Annual Meeting of the European Venous Forum; 24\u201326 June 2021; Virtual2021."},{"issue":"5","key":"2218_CR11","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1056\/NEJMra055289","volume":"355","author":"JJ Bergan","year":"2006","unstructured":"Bergan JJ, Schmid-Sch\u00f6nbein GW, Smith PD, Nicolaides AN, Boisseau MR, Eklof B. Chronic venous disease. N Engl J Med. 2006;355(5):488\u201398.","journal-title":"N Engl J Med"},{"key":"2218_CR12","doi-asserted-by":"crossref","unstructured":"Vincent JR, Jones GT, Hill GB, van Rij AM. Failure of microvenous valves in small superficial veins is a key to the skin changes of venous insufficiency. J Vasc Surg. 2011;54(6 Suppl):62S-9S.e1\u20133.","DOI":"10.1016\/j.jvs.2011.06.085"},{"issue":"1","key":"2218_CR13","first-page":"81","volume":"27","author":"J Paysant","year":"2008","unstructured":"Paysant J, Sansilvestri-Morel P, Bouskela E, Verbeuren TJ. Different flavonoids present in the micronized purified flavonoid fraction (Daflon 500 mg) contribute to its anti-hyperpermeability effect in the hamster cheek pouch microcirculation. Int Angiol. 2008;27(1):81\u20135.","journal-title":"Int Angiol"},{"issue":"3","key":"2218_CR14","first-page":"179","volume":"25","author":"A Nicolaides","year":"2018","unstructured":"Nicolaides A. The place of MPFF in the management of chronic venous disease. Phlebolymphology. 2018;25(3):179\u201388.","journal-title":"Phlebolymphology"},{"issue":"2","key":"2218_CR15","doi-asserted-by":"publisher","first-page":"143","DOI":"10.23736\/S0392-9590.18.03975-5","volume":"37","author":"SK Kakkos","year":"2018","unstructured":"Kakkos SK, Nicolaides AN. Efficacy of micronized purified flavonoid fraction (Daflon\u00ae) on improving individual symptoms, signs and quality of life in patients with chronic venous disease: a systematic review and meta-analysis of randomized double-blind placebo-controlled trials. Int Angiol. 2018;37(2):143\u201354.","journal-title":"Int Angiol"},{"issue":"8","key":"2218_CR16","doi-asserted-by":"publisher","first-page":"573","DOI":"10.2165\/00128071-200304080-00007","volume":"4","author":"M Simka","year":"2003","unstructured":"Simka M, Majewski E. The social and economic burden of venous leg ulcers: focus on the role of micronized purified flavonoid fraction adjuvant therapy. Am J Clin Dermatol. 2003;4(8):573\u201381.","journal-title":"Am J Clin Dermatol"},{"issue":"2","key":"2218_CR17","first-page":"107","volume":"49","author":"W Glinski","year":"2001","unstructured":"Glinski W, Chodynicka B, Roszkiewicz J, T, Lecewicz-Torun B, Kaszuba A, et al. Effectiveness of a micronized purified flavonoid fraction (MPFF) in the healing process of lower limb ulcers. An open multicentre study, controlled and randomized. Minerva Cardioangiol. 2001;49(2):107\u201314.","journal-title":"Minerva Cardioangiol"},{"issue":"1","key":"2218_CR18","first-page":"18","volume":"22","author":"YT Tsoukanov","year":"2015","unstructured":"Tsoukanov YT, Tsoukanov AY, Nikolaychuk A. Great saphenous vein transitory reflux in patients with symptoms related to chronic venous disorders, but without visible signs (C0s), and its correction with MPFF treatment. Phlebolymphology. 2015;22(1):18\u201324.","journal-title":"Phlebolymphology"},{"issue":"2","key":"2218_CR19","doi-asserted-by":"publisher","first-page":"189","DOI":"10.23736\/S0392-9590.16.03708-1","volume":"36","author":"YT Tsukanov","year":"2017","unstructured":"Tsukanov YT, Nikolaichuk AI. Orthostatic-loading-induced transient venous refluxes (day orthostatic loading test), and remedial effect of micronized purified flavonoid fraction in patients with telangiectasia and reticular vein. Int Angiol. 2017;36(2):189\u201396.","journal-title":"Int Angiol"},{"issue":"3","key":"2218_CR20","first-page":"144","volume":"24","author":"YT Tsukanov","year":"2017","unstructured":"Tsukanov YT, Tsukanov AY. Diagnosis and treatment of situational great saphenous vein reflux in daily medical practice. Phlebolymphology. 2017;24(3):144\u201351.","journal-title":"Phlebolymphology"},{"issue":"1","key":"2218_CR21","doi-asserted-by":"publisher","first-page":"132","DOI":"10.5455\/annalsmedres.2020.06.624","volume":"28","author":"MO Beyaz","year":"2021","unstructured":"Beyaz MO, Ata EC. Effects of diosmin-hesperidin and low pressure compression stocking combination in superficial venous insufficiency. Ann Med Res. 2021;28(1):132\u20135.","journal-title":"Ann Med Res"},{"issue":"2","key":"2218_CR22","first-page":"70","volume":"27","author":"VY Bogachev","year":"2020","unstructured":"Bogachev VY. Effectiveness of micronized purified flavonoid fraction-based conservative treatment in chronic venous edema. Phlebolymphology. 2020;27(2):70\u201380.","journal-title":"Phlebolymphology"},{"issue":"4","key":"2218_CR23","first-page":"310","volume":"31","author":"FA Allaert","year":"2012","unstructured":"Allaert FA. Meta-analysis of the impact of the principal venoactive drugs agents on malleolar venous edema. Int Angiol. 2012;31(4):310\u20135.","journal-title":"Int Angiol"},{"issue":"8","key":"2218_CR24","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1007\/s40267-019-00637-5","volume":"35","author":"V Bogachev","year":"2019","unstructured":"Bogachev V, Arribas JMJ, Baila S, et al. Management and evaluation of treatment adherence and effectiveness in chronic venous disorders: results of the international study VEIN Act Program. Drugs Ther Perspect. 2019;35(8):396\u2013404.","journal-title":"Drugs Ther Perspect"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-022-02218-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-022-02218-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-022-02218-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T02:12:26Z","timestamp":1662948746000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-022-02218-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,11]]},"references-count":24,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["2218"],"URL":"https:\/\/doi.org\/10.1007\/s12325-022-02218-x","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,11]]},"assertion":[{"value":"28 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}